Search

The purpose of this study was to determine the maximum daily patient-reported pain scores for those patients who experienced subarachnoid hemorrhage (SAH) and to assess how medications were used. A retrospective review of the electronic records of patients who experienced SAH was performed to evaluate patient demographics and comorbidities. The daily pain scores were statistically significant on day 5. Morphine equivalent dosing for day 1 admissions was as follows: patients with a Hunt and Hess (HH) score of I = 2.69, II = 5.52, and III = 0.86 (P = .009). Patients with SAH with an HH score of I and II had similar headaches but received more acetaminophen than patients with an HH score of III.AU

Background: Emergent Large Vessel Occlusion (ELVO) strokes are devastating ischemic vascular events for which novel biomarkers and therapies are needed. The purpose of this study is to investigate the role of Body Mass Index (BMI) on protein expression and signaling at the time of ELVO intervention. Methods: The Blood And Clot Thrombectomy Registry And Collaboration (BACTRAC) is a continually enrolling tissue bank (clinicaltrials.gov NCT03153683) from stroke patients undergoing mechanical thrombectomy (MT). N=61 human carotid plasma samples were analyzed for inflammatory and cardiometabolic protein expression by Olink Proteomics. Results: The 61 subjects studied were broken into three categories: Normal weight (BMI 18.5-24.9) which contained 19 subjects, Overweight (BMI 25-30) which contained 25 subjects, and Obese (BMI ≥30) which contained 17 subjects. When compared to Normal weight and Overweight categories, the Obese category had significantly higher levels of adenosine deaminase (ADA) expression (p=0.01 and p=0.039, respectively). Elevated levels of ADA were found to have a significant positive correlation with both infarct volume and edema volume (p=0.013 and p=0.041, respectively), and were associated with a more severe stroke (NIHSS on discharge) and greater stroke-related disability (mRS on discharge) with significance of p=0.053 and p=0.032, respectively). When controlling for age and sex, increased infarct volumes were predicted by higher ADA levels in the Obese population (p=0.009), while increased ADA levels were not predictive of increased infarct volumes in the Normal weight category. Conclusions: When examined according to BMI, subjects undergoing MT for ELVO demonstrate significant differences in the expression of certain plasma proteins including ADA. The protein ADA is a deaminating enzyme that degrades adenosine, which has been shown to be neuroprotective in ischemia. Increased levels of ADA in the Obese group were predictive of increased infarct volumes. Further testing will explore the relationship of BMI and ADA on cognitive function outcomes. These data provide novel biomarker candidates as well as treatment targets while increasing the personalization of stroke prognosis and treatment.

This meeting abstract was removed due to the OA licensing requirements of this journal. The full abstract is listed here : https://www.svin.org/files/SVIN_2021_Abstracts_for_Web.pdf

Supplemental Digital Content is available in the text., Background and Purpose: Stent-assisted coil embolization using the new generation Neuroform Atlas Stent System has shown promising safety and efficacy. The primary study results of the anterior circulation aneurysm cohort of the treatment of wide-neck, saccular, intracranial, aneurysms with the Neuroform Atlas Stent System (ATLAS trial [Safety and Effectiveness of the Treatment of Wide Neck, Saccular Intracranial Aneurysms With the Neuroform Atlas Stent System]) are presented. Methods: ATLAS IDE trial (Investigational Device Exemption) is a prospective, multicenter, single-arm, open-label study of wide-neck (neck ≥4 mm or dome-to-neck ratio 50%) at the target location. The primary safety end point was any major stroke or ipsilateral stroke or neurological death within 12 months. Adjudication of the primary end points was performed by an independent Imaging Core Laboratory and the Clinical Events Committee. Results: A total of 182 patients with wide-neck anterior circulation aneurysms at 25 US centers were enrolled. The mean age was 60.3±11.4 years, 73.1% (133/182) women, and 80.8% (147/182) white. Mean aneurysm size was 6.1±2.2 mm, mean neck width was 4.1±1.2 mm, and mean dome-to-neck ratio was 1.2±0.3. The most frequent aneurysm locations were the anterior communicating artery (64/182, 35.2%), internal carotid artery ophthalmic artery segment (29/182, 15.9%), and middle cerebral artery bifurcation (27/182, 14.8%). Stents were placed in the anticipated anatomic location in all patients. The study met both primary safety and efficacy end points. The composite primary efficacy end point of complete aneurysm occlusion (Raymond-Roy 1) without parent artery stenosis or aneurysm retreatment was achieved in 84.7% (95% CI, 78.6%–90.9%) of patients. Overall, 4.4% (8/182, 95% CI, 1.9%–8.5%) of patients experienced a primary safety end point of major ipsilateral stroke or neurological death. Conclusions: In the ATLAS IDE anterior circulation aneurysm cohort premarket approval study, the Neuroform Atlas stent with adjunctive coiling met the primary end points and demonstrated high rates of long-term complete aneurysm occlusion at 12 months, with 100% technical success and